Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening

doi:10.1016/S0140-6736(02)07339-7

The Lancet

Volume 359, Issue 9301, 12 January 2002, Pages 133-135

https://doi.org/10.1016/S0140-6736(02)07339-7 Get rights and content

Summary

We investigated the relation between positivity for hepatitis C virus (HCV) and carotid-artery plaque and carotid intima-media thickening by analysing cross-sectional data of individuals undergoing a general health screening test. Of 4784 individuals enrolled, 104 (2·2%) were seropositive for HCV. After adjustment for confounding risk factors, HCV seropositivity was found to be associated with an increased risk of carotid-artery plaque (odds ratio 1·92 [95% CI 1·56–2·38], p=0·002) and carotid intima-media thickening (2·85 [2·28–3·57], p<0·0001). These findings suggest a possible role for chronic hepatitis C in the pathogenesis of carotid arterial remodelling.

References (5)

KiechlS et al.
Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study
Circulation
(2001)
ZhuJ et al.
The possible role of hepatitis A virus in the pathogenesis of atherosclerosis
J Infect Dis
(2000)

There are more references available in the full text version of this article.

Cited by (240)

Cardioprotective effect of antiviral therapy among hepatitis C infected patients: A meta-analysis
2023, IJC Heart and Vasculature
Hepatitis C (HCV) infections have been shown to be associated a with higher risk of atherosclerotic cardiovascular disease (CVD). However, the use of antiviral therapy (AVT) and the risk of CVD has not been well established with limited literature.
We sought to evaluate the association between AVT use post-HCV infection and cardiovascular outcomes.
We performed a systematic literature search using PubMed, Embase, and Scopus for relevant articles from inception until 10th March 2023. Primary clinical outcomes were the incidence of any CVD. Secondary endpoints were all-cause of mortality, stroke, myocardial infarction, and peripheral artery disease.
A total of 394,452 patients were included in the analysis (111,076 in the AVT group and 283,376 patients in the NAVT group). The mean age of patients among AVT and NAVT groups was comparable (58.7 vs 58.18). The pooled analysis of primary outcomes showed that AVT was associated with a significantly reduced risk of any CVD (HR, 0.55(95%CI: 0.41–0.75), P < 0.001) compared with the NAVT group of patients. Secondary outcomes including ACM (HR, 0.38(95%CI: 0.32–0.46), P < 0.001), MI (HR, 0.62(95%CI: 0.41–0.94), P = 0.02), and PAD (HR, 0.62(95%CI: 0.41–0.93), P = 0.02) were significantly lower among AVT groups compared with NAVT groups of patients with HCV infection. However, the risk of stroke was comparable between both groups of patients (HR, 0.79(95%CI: 0.58–1.07), P = 0.13).
Our analysis shows HCV-infected patients post-AVT have a significantly lower risk of any CVD, MI, ACM, and PAD compared with NAVT groups of patients.
Hepatic Interactions in Atherosclerotic Heart Disease
2022, American Journal of the Medical Sciences
Atherosclerotic heart disease remains a major cause of morbidity and mortality worldwide. The past few decades have seen the emergence of chronic inflammation as a mediator of atherosclerosis. Although the heart and vascular system remain the organ systems most affected in the atherosclerotic process, chronic inflammation and ischemia trigger a systemic multi-organ response. The liver is a critical organ for systemic hemostasis and recent developments have established an important role of the liver in response to atherosclerosis and myocardial ischemia. In addition, the rapid emergence of systemic liver diseases has unraveled a pathophysiological link with heart disease with therapeutic implications. In this review, we explore the relationship between the liver and the heart in myocardial ischemia, describe epidemiological associations between various liver pathologies and coronary heart disease, and elucidate practical challenges in the clinical management of patients with concomitant coronary heart disease and hepatic abnormalities.
Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradication
2019, JHEP Reports
Patients with HCV-related bridging fibrosis or cirrhosis remain at risk of developing life-threatening complications even after achieving a sustained virological response. Although it is reduced, the risk of liver-related events in these patients justifies their inclusion in surveillance programmes dedicated to the early detection of hepatocellular carcinoma and the screening for portal hypertension. Biochemical parameters or non-invasive tests might indicate the potential progression of liver injury despite viral clearance. Specific attention must be focused on the management of comorbidities, while dedicated educational programmes must be encouraged to increase compliance and commitment to surveillance. Better knowledge of the long-term evolution of these patients, who now live longer, is essential to improve risk stratification and refine screening strategies in this growing population.
Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation
2024, AIDS
Hepatitis C and heart transplantation: An update
2023, Clinical Transplantation
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study
2023, European Heart Journal - Cardiovascular Pharmacotherapy

View all citing articles on Scopus

View full text

Research LettersAssociation between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening

Summary

Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study

Circulation

The possible role of hepatitis A virus in the pathogenesis of atherosclerosis

J Infect Dis

Research Letters
Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening